Mitoxantrone-cytarabine-etoposide induction therapy in children with acute myeloid leukemia: a single-center study of complications and clinical outcomes
CHEN Xiao-Yan, RUAN Min, ZHAO Bei-Bei, WANG Shu-Chun, CHEN Xiao-Juan, ZHANG Li, GUO Ye, YANG WenYu, ZOU Yao, CHEN Yu-Mei, ZHU Xiao-Fan
Department of Pediatric Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
Abstract Objective To investigate the complications and clinical outcome of children with acute myeloid leukemia (AML) undergoing mitoxantrone-cytarabine-etoposide (MAE) induction therapy. Methods A total of 170 children with AML were given MAE induction therapy, and the complications and remission rate were analyzed after treatment. Results The male/female ratio was 1.33:1 and the mean age was 7.4 years (range 1-15 years). Leukocyte count at diagnosis was 29.52×109/L[range (0.77-351)×109/L]. Of all children, 2 had M0-AML, 24 had M2-AML, 2 had M4-AML, 48 had M5-AML, 3 had M6-AML, 7 had M7-AML, 69 had AML with t(8;21)(q22;q22), and 15 had AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22). The most common complication was infection (158/170, 92.9%). Among these 158 patients, 22 (13.9%) had agranulocytosis with pyrexia (with no definite focus of infection), and 136 (86.1%) had definite focus of infection (including bloodstream infection). Other complications included non-infectious diarrhea, bleeding, and drug-induced hepatitis. Treatment-related mortality was observed in 10 children, among whom 8 had severe infection, 1 had multiple organ failure, and 1 had respiratory failure. Remission rate was evaluated for 156 children and the results showed a complete remission rate of 85.3%, a partial remission rate of 4.5%, and a nonremission rate of 10.3%. Conclusions Induction therapy with the MAE regimen helps to achieve a good remission rate in children with AML after one course of treatment. Infection is the main complication and a major cause of treatmentrelated mortality.
CHEN Xiao-Yan,RUAN Min,ZHAO Bei-Bei et al. Mitoxantrone-cytarabine-etoposide induction therapy in children with acute myeloid leukemia: a single-center study of complications and clinical outcomes[J]. CJCP, 2019, 21(1): 24-28.
CHEN Xiao-Yan,RUAN Min,ZHAO Bei-Bei et al. Mitoxantrone-cytarabine-etoposide induction therapy in children with acute myeloid leukemia: a single-center study of complications and clinical outcomes[J]. CJCP, 2019, 21(1): 24-28.
Papaemmanui E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia[J]. N Engl J Med, 2016, 374(23):2209-2221.
[2]
Gamis AS, Alonzo TA, Perentesis JP, et al. Children's Oncology Group's 2013 blueprint for research:acute myeloid leukemia[J]. Pediatr Blood Cancer, 2013, 60(6):964-971.
[3]
Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia:a retrospective analysis of the AML-BFM trials from 1987 to 2012[J]. Leukemia, 2018, 32(10):2167-2177.
[4]
Vardiman JW, Thiele J, Arber DA, et a. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes[J]. Blood, 2009, 114(5):937-951.
U.S. Department of Health and Human Services, National Institutes of Health/National Cancer Institute. Terminology Criteria for Adverse Events (CTCAE) version 4.0.3[EB/OL]. (May 28, 2009). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
[7]
Zwaan CM, Kolb EA, Reinhard D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia[J]. J Clin Oncol, 2015, 33(27):2949-2962.
[8]
Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia:the AML99 trial from the Japanese Childhood AML Cooperative Study Group[J]. J Clin Oncol, 2009, 27(24):4007-4013.
[9]
Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia:analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98[J]. J Clin Oncol, 2004, 22(21):4384-4393.
[10]
Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia:analysis of the prospective multi-institutional clinical trial AML-BFM 93[J]. Leukemia, 2004, 18(1):72-77.
[11]
Inaba H, Gaur AH, Cao X, et al. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia[J]. Cancer, 2014, 120(13):1985-1992.
[12]
Sung L, Aplenc R, Alonzo TA, et al. Effectiveness of supportive care measures to reduce infections in pediatric AML:a report from the Children's Oncology Group[J]. Blood, 2013, 121(18):3573-3577.
[13]
Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia:results of AML-BFM 98[J]. J Clin Oncol, 2006, 24(27):4499-4506.
[14]
Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colonystimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse[J]. J Clin Oncol, 2010, 28(15):2591-2597.
[15]
Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer:a meta-analysis of randomized controlled trials[J]. J Clin Oncol, 2004, 22(16):3350-3356.
[16]
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4):424-447.
